KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Globus Medical (GMED) Common Equity (2016 - 2025)

Globus Medical (GMED) has disclosed Common Equity for 15 consecutive years, with $4.6 billion as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Common Equity rose 9.48% year-over-year to $4.6 billion, compared with a TTM value of $4.6 billion through Dec 2025, up 9.48%, and an annual FY2025 reading of $4.6 billion, up 9.48% over the prior year.
  • Common Equity was $4.6 billion for Q4 2025 at Globus Medical, up from $4.4 billion in the prior quarter.
  • Across five years, Common Equity topped out at $4.6 billion in Q4 2025 and bottomed at $1.6 billion in Q1 2021.
  • Average Common Equity over 5 years is $3.0 billion, with a median of $3.0 billion recorded in 2023.
  • The sharpest move saw Common Equity soared 137.36% in 2023, then decreased 2.82% in 2024.
  • Year by year, Common Equity stood at $1.7 billion in 2021, then increased by 6.03% to $1.8 billion in 2022, then soared by 116.53% to $4.0 billion in 2023, then grew by 4.49% to $4.2 billion in 2024, then grew by 9.48% to $4.6 billion in 2025.
  • Business Quant data shows Common Equity for GMED at $4.6 billion in Q4 2025, $4.4 billion in Q3 2025, and $4.3 billion in Q2 2025.